Thrombosis and Haemostasis · 2002 · 28 citations · 9 references
PharmacyPharmacokineticsPharmacologyBioavailabilityClinical PharmacologyDrug DeliveryBioavailability AnalysisIntravenous Drug DeliveryParenteral FormulationsPharmacokinetics Across SpeciesConcentrationHigh-concentration FormulationsPharmacokinetic Bioavailability AnalysisRecombinant Activated Factor ViiSubcutaneous Drug AdministrationSubcutaneous Medication AdministrationVeterinary Pharmaceutical FormulationsVeterinary Pharmacokinetics
Hemophilia B therapy requires intravenous (IV) infusions of large volumes of factor IX due to the low concentration of factor IX in concentrates (approximately 100 IU/mL). High concentration recombinant factor IX (rFIX) could be a significant advance since it would reduce the large volumes necessary for IV dosing and allow for low-volume subcutaneous (SC) administration. To evaluate high concentration factor IX, we produced formulations with either 2,000 or 4,000 IU/mL and studied the SC bioavailability in beagle dogs, cynomolgus monkeys and hemophilia B dogs along with efficacy in hemophilia B dogs. Beagle dog SC bioavailability was 86.4% using a 2000 IU/mL formulation and 77.0% using a 4000 IU/mL formulation. Monkey bioavailability of a 4000 IU/mL formulation of rFIX was 34.8%. A single SC administration of 200 IU/kg (4000 IU/mL) of rFIX to hemophilia B dogs, produced factor IX clotting activity above 5% for 5 days with a bioavailability of 48.6%. High concentration SC rFIX has an acceptable pharmacokinetic profile in monkeys and dogs, and produces a sustained FIX activity in hemophilic dogs.
9
Haemophilia prophylaxis in young patients–a long‐term follow‐up
Thomas Löfqvist, Inga Marie Nilsson, Erik Berntorp et al. · Journal of Internal Medicine · 1997 · 338 citations · Full text
Results of secondary prophylaxis in children with severe hemophilia
Marilyn J. Manco‐Johnson, Rachelle Nuss, Susan J. Geraghty et al. · American Journal of Hematology · 1994 · 151 citations
Medicine, Hematology, Pediatrics +15
The manufacturing process for recombinant factor IX.
Scott H. Harrison, S. Robert Adamson, D Bonam et al. · Seminars in Hematology · 1998 · 65 citations